Adverse Bleeding and Monitoring Guidelines for Adolescents on SSRIs

Bleeding Risks Associated with SSRI Use

• The American Academy of Child and Adolescent Psychiatry identifies ecchymosis, hematoma, epistaxis, petechiae, and hemorrhage as rare but documented bleeding events in adolescents treated with SSRIs【1】【2】.
• The risk of abnormal bleeding is markedly increased when an SSRI is combined with aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs)【1】【2】【3】.

Recommended Monitoring Framework

• The GLAD‑PC (Guidelines for Adolescent Depression in Primary Care) recommends that primary‑care clinicians monitor for adverse events throughout SSRI therapy with a very strong recommendation strength【4】【5】【6】.
• At each clinical visit, clinicians should explicitly assess:

Clinical Assessment Actions When Bruising Is Reported

• Review the patient’s medication list for concurrent use of NSAIDs, aspirin, anticoagulants, or other agents that may potentiate bleeding risk【1】【2】【3】.

Management Strategies for SSRI‑Related Bleeding

• If bruising appears dose‑related, consider reducing the SSRI dose【1】【2】.
• Discontinue the SSRI if bleeding is significant or progressive (clinical judgment required).
• When discontinuation is necessary, switch to an alternative antidepressant treatment【4】【5】.

Regulatory and Safety Oversight

• The U.S. Food and Drug Administration (FDA) mandates close observation of all pediatric patients receiving antidepressants, especially during the initial months of therapy or after dose adjustments; any bleeding event such as bruising must be reported and evaluated【4】【5】【6】.